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Studies on infection-induced inflammatory reactions in humans rely largely on findings in the blood compartment. Peritoneal
leukocytes from patients treated with peritoneal dialysis oﬀer a unique opportunity to study in humans the inflammatory
responses taking place at the site of infection. Compared with peritoneal macrophages (pMφ) from uninfected patients, pMφ
from infected patients display ex vivo an upregulation and downregulation of proinflammatory and anti-inflammatory mediators,
respectively. Pro-IL-1β processing and secretion rather than synthesis proves to be increased in pMφ from infectious peritonitis
suggesting up-regulation of caspase-1 in vivo. A crosstalk between pMφ, γδ T cells, and neutrophils has been found to be
involved in augmented TNFα expression and production during infection. The recent finding in experimental studies that
alternatively activated macrophages (Mφ2) increase by proliferation rather than recruitment may have significant implications
for the understanding and treatment of chronic inflammatory conditions such as encapsulating peritoneal sclerosis (EPS).
1. Introduction
Continuous ambulatory peritoneal dialysis (CAPD) was
introduced in 1978 as a new treatment modality for patients
with end-stage renal failure. In CAPD, after infusion of
typically 2 litres of dialysis fluid via a catheter into the
peritoneal cavity, retainedmetabolites diﬀuse from the blood
to the peritoneal cavity during a dwell time of 4 to 8 hours,
after which the dialysis fluid is drained and replaced with
fresh dialysis fluid. In this way, the patient exchanges 3–5
times a day dialysis fluid. A major complication of CAPD
is peritonitis caused by contamination by microorganisms
that can enter the peritoneal cavity via infusion of dialysis
fluid during the exchange, or by spreading of an infection
from the skin and tissue around the catheter to the peritoneal
cavity, or from the intestines [1]. In the early years, an
episode of peritonitis occurred on average one time per 8
treatment months, but since the nineties the frequency was
substantially reduced to one time every 24 months due to
novel connections of the infusion systems. These so-called
“flush-before-fill” systems reduce the risk of peritonitis dur-
ing the exchange of dialysis fluids, which is caused especially
by coagulase negative Staphylococci and other gram positive
microorganisms. Infectious peritonitis is characterized by
abdominal pain and turbid drained dialysate (peritoneal
eﬄuent) due to an increased number of leukocytes more
than 50% of which are neutrophilic PMN’s. Peritonitis is
almost invariably revealed by opalescence of dialysate, which
is noticed by patients when the leucocyte count is greater
than 100/mm3. The majority of peritonitis episodes can be
treated successfully with the intraperitoneal administration
of antibiotics while continuing CAPD.
Infectious peritonitis in CAPD patients has been shown
to provide a unique opportunity to study the inflamma-
tory reactions in humans at the site of inflammation by
studying cellular players including macrophages, lympho-
cytes, granulocytes, and mesothelial cells as well as soluble
mediators present in peritoneal eﬄuent [2–4]. In this paper,
various studies are reviewed that are conducted in the past
few decades on this topic with emphasis on the role of
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macrophages (Mφ) and cytokines. The findings will be put
in the context of new insights that developed the past decade
in the biology of Mφ and cytokines. Studying leukocytes
from an inflammatory environment can make a valuable
contribution to a better understanding of inflammatory
reactions in humans.
2. Macrophages, Heterogeneity
versus Polarization
Tissue Mφ are derived from circulating blood monocytes,
which in turn arise from their bone marrow precursors.
These cells together make up the mononuclear phagocyte
system, as described by van Furth and Cohn [5]. After mono-
cytes have entered the tissues to become Mφ, they have the
potential to acquire a variety of diﬀerent functional attributes
depending on signals they receive from the environment.
Thus, the mononuclear phagocyte system consists of a
heterogeneous and highly versatile, multipotential cell popu-
lation. The diﬀerentiation and activation to diverse functions
in the tissues are governed by the presence of regulatory
signals in the environment and occur in several distinct steps
[6]. In the past decade, a new view on Mφ diﬀerentiation
and activation has been developed. In vitro two types of Mφ
are distinguished: Classically activated Mφ display a pro-
inflammatory profile, induced by IFN-γ or LPS, whereas
alternatively activated Mφ express anti-inflammatory and
tissue repair properties induced by IL-4 or IL-13 [7–11]. IFN-
γ is a prototypical Th-1 cell secretory product, while IL-4
and IL-13 are produced by Th-2 cells andMφ. Classically and
alternatively activated Mφ are also named as Mφ1 and Mφ2,
mirroring the Th-1 and Th-2 polarization, respectively. Type
1 and type 2 inflammation represent ancient innate pathways
with fundamentally diﬀerent purposes. Type 1 promotes
killing of microbial pathogens and intracellular parasites
and is involved in tissue destruction and tumor resistance.
Type 2 participates in tissue repair and controls infection
with macroparasites through encapsulation. Mφ1 typically
show a high expression of the cytokines IL-12, IL-23, TNFα,
IL-1β, and Mφ1 chemokines and are eﬃcient producers
of reactive oxygen and nitrogen intermediates, whereas IL-
10 production is low. In contrast, in Mφ2 expression of
IL-12, IL-23, TNFα, and IL-1β is low, whereas expression
of IL-10, IL-1ra, TGFβ, Mφ2 chemokines and scavenger,
mannose and galactose receptors is high. In experimental in
vivo studies, it has been found that a subset of patrolling,
circulating monocytes, which may correspond to human
CD16+ monocytes, are rapidly recruited to the peritoneal
cavity, peaking at 2 hours after infection with Listeria
monocytogenes, when PMN is only beginning to enter the
peritoneal cavity [12]. After 1 and 2 hours after infection
these mononuclear phagocytes produce TNFα and show an
upregulated expression of genes coding for IL-1 and various
chemokines and pattern recognition receptors such as toll-
like receptors (TLRs). Notably, the production of TNFα
and IL-1β is transient and turns oﬀ at 8 hours, whereas
these mononuclear phagocytes turn on, at 2 and 8 hours,
in genes involved in tissue remodeling. A diﬀerent subset
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Figure 1: Simplified model of the paradigm of polarized
macrophage activation. Monocytes are either classically (Mφ1) or
alternatively (Mφ2) activated. Substances such as IFN-γ and LPS
induce classical activation while IL-4, IL-13, and TGFβ cause alter-
native activation. Mφ1macrophages typically produce high levels of
proinflammatory proteins including TNFα, IL-1β, IL-12, and IL-23
as well as reactive oxygen and nitrogen intermediates. Mφ2 produce
high levels of the anti-inflammatory cytokines IL-10 and IL-1ra
and show a high expression of scavenger and mannose receptors.
Under the influence of IL-4, Mφ2 can accumulate in tissues by
local proliferation rather than by recruitment. Either functional
phenotype can shift to another depending on microenvironmental
influences, speaking against rigid interpretation of the dichotomy
between the macrophage phenotypes.
of conventional monocytes arrive later and give rise to
inflammatory dendritic cells (DCs) and Mφ1 macrophages
[8, 12]. In a recent experimental study, it was found that
both resident and recruited Mφ can be alternatively activated
and be driven to proliferate in situ by a Th-2 environment
in vivo, implying that there is neither a specific precursor
for Mφ2 nor is proliferative capacity restricted by lineage
[13]. While the paradigm of macrophage dichotomy is well
established, employing it as a rigid scheme could bring
about a risk of oversimplification. Thus, Mφ can reversibly
shift their functional phenotype through a multitude of
patterns in response to changes in cytokine environment,
as illustrated in Figure 1 [14]. In humans, arginase, which
is considered to be characteristic of alternatively activated
macrophages, is not expressed prominently IL-4-induced
Mφ2 macrophages [15]. Furthermore, during the resolution
phase of experimental inflammation a Mφ phenotype with
properties of both Mφ1 and Mφ2 could be distinguished
[16].
3. Peritoneal Macrophage (pMφ)
from CAPD Patients
Approximately 1–40 millions of leukocytes can be col-
lected from peritoneal eﬄuent after a dwell time of 6–
8 hours. The yield decreases in the course of CAPD
treatment. In uninfected patient, the leukocyte population
was found to be composed of 85% mononuclear phagocytes
by nonspecific esterase staining, while >75% of each cell
population was HLA-DR+. Six percent were neutrophilic
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and/or eosinophilic PMNs [17, 18]. Using flow cytometric
analysis for surface markers, about 40% of the peritoneal
cells were identified as lymphocytes [19]. Various subsets
are distinguished in peritoneal lymphocytes including B cells
and various subsets of T cells. Two to six percent of peritoneal
cells can be characterized as DC’s, which are diﬀerentiated
in the peritoneal cavity from monocyte-derived CD14+
cells [20, 21]. Peritoneal CD14+ cells were characterized
as Mφ2 macrophages on the basis of a CD163+CD16−
phenotype, a high capacity for phagocytosis and production
of high amounts of IL-10, sharing these properties with
in vitro polarized Mφ2 [19]. In contrast, the production
of substantial amounts of IL-6, as found in this study,
is a property of Mφ1 rather than Mφ2. The CAPD cell
population is continually renewed and is exposed to dialysis
fluids with an unphysiological composition and to the
dialysis catheter. Yet, in many respects the macrophages
from CAPD patient bear resemblance to those from healthy
women undergoing laparoscopy [17, 18]. Compared with
such cells from rats, CAPD pMφ resemble starch-elicited
rather than resident cells [22].
When a peritoneal infection becomes clinically manifest,
there is a sharp, up to 100 fold increase in peritoneal leuko-
cytes, 50–90% of which are neutrophils. Also the number
of pMφ, dendritic cells and various subsets of lymphocytes
show a marked increase, including γδ T cells [20, 23].This
minisubset is rapidly recruited to the inflammatory site and
responds to the microbial molecule HMB-PP that is found
in various species—30% to 50% of peritonitis episodes
is caused by HMB-PP+ microbes—and is released when
microorganisms are killed by other leukocytes including neu-
trophils [24]. By interaction of γδ T cells with mononuclear
phagocytes, the inflammatory reaction is amplified. Already
one to two days before the infection becomes clinically
manifest, an increased number of pMφ and neutrophils
is found [25]. Following appropriate antibiotic treatment,
the mononuclear cells and especially the neutrophils show
a sharp drop in the next few days, resulting in a relative
increase of pMφ and lymphocytes. While on the first day
of the peritonitis pMφ outnumber lymphocytes, in the
resolution phase the macrophages/lymphocytes ratio is
reversed [26]. Using flow cytometry, pMφ from infected
patients displayed an increased expression and production
of selected Mφ2-associated cell surface markers (CD163+)
and chemokines (CCL18), respectively, but expression of
the Mφ2-associated mannose receptor CD206+ was lower
in peritonitis pMφ. Gene expression of TGF-β1, metallopro-
teinase 9 (MMP9), and CCL18 in pMφ from infected and
uninfected patients were similar [27].
4. Cytokines in CAPD during
Infectious Peritonitis
The pro-inflammatory cytokines IL-1β, TNFα, and IL-6 play
a key role in the inflammatory response. By exerting their
pleiotropic eﬀects in an autocrine, paracrine, and endocrine
fashion, these cytokines are able to orchestrate the inflamma-
tory responses. Although they can be produced by various
cells, macrophages are the prototypical cell source. PMφ
from CAPD patients collected during infectious peritonitis,
showed amarked increase in the secretion of TNFα and IL-1β
as compared with macrophages from infection free patients,
when they were stimulated ex vivo with LPS [28, 29]. In con-
trast, unstimulated pMφ secreted similar amounts of TNFα
and IL-1β ex vivo in pMφ from patients with and without
infection. These findings are in line with the paradigm of
stepwise activation of Mφ. On the other hand, the ex vivo
secretion of the anti-inflammatory IL-10 was decreased in
peritonitis macrophages, in line with a pro-inflammatory
phenotype [30]. In the eﬄuent from patients with infectious
peritonitis, as compared with uninfected patients, increased
levels of various pro-inflammatory cytokines were found,
including IL-1β, IL-8, TNFα, IL-6, and IFNγ [26, 31–35].
Remarkably, also levels of anti-inflammatory cytokines for
example, TGFβ and IL-1ra were elevated [26, 32, 36]. It
should be noted that in addition toMφ and other leukocytes,
mesothelial cells may also contribute substantially to the
production of various cytokines including IL-6 and IL-8
[37, 38].
We investigated at which level the increased capability
of peritonitis pMφ to secrete IL-1β after ex vivo stimulation
with LPS occurs, using ELISA’s specific to the 32 kDa,
biologically inactive pro-IL-1β and the mature 17 kDa,
bioactive IL-1β [39]. Pro-IL-1β processing and subsequent
release of mature IL-1β (mIL-1β) rather than its production
were found to be increased in peritonitis pMφ (Figures
2(a), 2(b), and 2(c)), suggesting increased caspase-1 activity.
Caspase-1 is present in the cell as the bioinactive pro-
caspase-1 to become a bioactive cysteine protease after
autocleavage. In the last decade, the understanding of the
molecular mechanisms behind caspase-1 activation has been
significantly increased. Briefly, NOD-like receptors (NLRs),
present in the cytosol, recognize microbial molecules leading
to oligomerization of NLRs and along with recruited pro-
caspase-1 and other proteins, to the forming of multiprotein
inflammasome complexes [40]. This results in auto-cleavage
and activation of caspase-1, whereupon pro-IL-1β is cleaved
and mIL-1β is released by an unconventional, poorly
understood, mechanism as IL-1β lacks a signal peptide
[41]. Microbial ligands induce transcription of pro-IL-
1β and inflammasome components by activation of the
transmembrane TLRs. Taken together, in the setting of our
study increased caspase-1 activation might be postulated as
priming mechanism in vivo. Interestingly, in a study using
high-density oligonucleotide microarrays to investigate
the transcriptional profile induced in human monocytes
by IL-13, one the most striking findings, besides a variety
of other characteristic genetic markers of alternatively
activated macrophages, was downregulation of caspase-1
and changes in other components of the IL-1 system such as
up-regulation of IL-1ra [15]. The LPS-inducible caspase-1
activity was also found to be reduced, resulting in a decrease
in pro-IL-1β processing. Further studies are needed to reveal
which molecular mechanisms account for the increased IL-
1β processing and export in peritonitis pMφ. We also found
that LPS stimulated not only pro-IL-1β production but also
release of mIL-1β in a dose-dependent fashion, suggesting
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Figure 2: Continued.
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Figure 2: Peritoneal macrophages (pMφ) were isolated from CAPD patients who were at least 3 months infection free (IF), or during
an episode of infectious peritonitis (P), prior to the start of treatment with antibiotics. 1.106 Cells were incubated ex vivo during 24 h in
medium or 5 μ/mL of LPS. Cytokines were determined in supernatants or cell lysates using ELISA. (a) Pro-IL-1β production and processing
and mIL-1β release. Quantities of pro-IL-1β (black bars) and mature IL-1β (mIL-1β) (white bars), expressed in pg/106 cells/24 h, using
ELISA specific for either form of IL-1β (CISTRONR), in supernatants and cell lysates from pMφ isolated during IF-period (n = 8) or P
(n = 10) and incubated in medium alone (a) or 5 μ/mL of LPS (b). Values are expressed as (M ± SEM). mIL-1β levels in supernatants from
LPS-stimulated pMφs were significantly higher when cells were isolated during P (P < 0.05), while pro-IL-1β in cell lysates was decreased
(P ≈ 0.05). (c) total IL-1β production (= pro-IL-1β + mIL-1β in supernatants + cell lysates) expressed in pmol/106 cells/24 h for each
IF-period (circles) and P episode (triangles) in LPS stimulated pMφ. Diﬀerence between total IL-1β production from IF and P pMφ was
not statistically significant. fraction of total IL-1β that is released in supernatant as mIL-1β, expressed as percentage. Fractional release from
peritonitis pMφ was significantly higher (P < 0.005). (d) total IL-1β production and fractional mIL-1β release in response to increasing
doses of LPS in pMφ isolated during 3 episodes of peritonitis, expressed in pmol/106 cells/24 h. Total IL-1β production increased in a dose-
dependent fashion. Within the range of 5.10−9–5.10−6 g/mL, LPS induced a dose-related increase in fractional IL-1β release. (e) release of
IL-1β and IL-1ra in supernatants from infection-free (n = 15) and peritonitis pMφ (n = 8) stimulated with and without 5 μg/mL of LPS.
Substantial amounts of IL-1ra were released in unstimulated cells. LPS-stimulated peritonitis pMφ released similar quantities of IL-1β and
IL-1ra.
a stimulating eﬀect of LPS on caspase-1 activity.
(Figure 2(d)) PMφ displayed a rather high constitutive
production of IL-1ra that further increased by stimulation
with LPS, with pMφ from infection-free and peritonitis
patients releasing similar amounts (Figure 2(e)). It has been
reported that a 10–500 fold molecular excess of IL-1ra is
required to obtain 50% inhibition of IL-1 biological eﬀects in
vitro [42]. In our study, similar amounts of IL-1ra and IL-1β
were released in LPS-stimulated peritonitis pMφ implying
a virtually unimpeded secreted IL-1 bioactivity. There was
no production of the bioactive form of IL-12 (Figure 3(a)).
The secretion of the anti-inflammatory cytokine IL-10 by
LPS-stimulated peritonitis pMφ was significantly reduced
(Figure 3(b)). However, IL-10 levels in peritoneal eﬄuent
were higher during peritonitis. The large increase in
macrophages and other leukocytes during peritonitis,
probably accounts for the discrepancy in the direction of
the changes of IL-10 and other anti-inflammatory cytokines
between macrophage cultures and peritoneal eﬄuents.
Absorption of pro- and anti-inflammatory cytokines from
the infectious inflammatory site might oﬀer in part an
explanation for the discrepancy in the blood compartment
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Figure 3: (a) Patients and methods as in Figure 1. Ex vivo IL-12p40 release is stimulated by LPS. Diﬀerence between pMφ from an infection-
free period (n = 8) and an episode of peritonitis (n = 8), was statistically not significant. Using an ELISA specific to the bioactive, hetero-
dimeric IL-12p70, no active IL-12 was detectable in supernatants from uninfected patients (n = 5) nor in those with peritonitis (n = 5),
whether or not the cells were stimulated with LPS. Consistent with this finding, virtually no IL-12p35 mRNA was expressed (data not shown).
All peritonitis episodes were caused by gram positive bacteria. (b) ex vivo IL-10 release from pMφ from infected patients (n = 8) is decreased
as compared with pMφ from an infection free environment (n = 8), (P < 0.01). IL-10 levels in peritoneal eﬄuents from peritonitis were
higher compared with infection-free eﬄuents, 235 pg/mL and 25 pg/mL, respectively (data not shown in figure).
between higher levels of circulating pro-inflammatory
cytokines and a decreased capacity of blood monocytes to
secrete TNFα and IL-1β as found in patients with sepsis.
Compartmentalization of the inflammatory response is a
key feature of the sepsis syndrome [43].
PMφ from infected patients have also an increased
capability to release TNFα [29]. PGE2 has been found to have
strongly inhibitory eﬀects on LPS-stimulated TNFα release,
almost eliminating the actions of LPS in a clearly dose-
related fashion, whereas cyclooxygenase inhibition caused an
increase in TNFα release [44]. The PGE2-induced down-
regulation, which was similar for pMφ from an infectious
or infection-free environment, is probably brought about
via elevation of intracellular cAMP levels. Moreover, it has
been found that peritonitis macrophages have suppressed
cAMP levels and a diminished release of prostaglandins
compared to uninfected macrophages [45, 46]. Similarly,
ex vivo stimulation of pMφ from uninfected patients with
Staphylococcus epidermidis induced a marked decrease of
cyclooxygenase products [47]. Prostaglandins are known
for their pro-inflammatory eﬀects, notably on the vascular
components of inflammatory reactions, but in various
settings these short-lived and locally acting substances have
proved to possess anti-inflammatory properties as well.
Recently it was reported, that, using low-dose and high-dose
zymosan induced peritonitis as a model for self-limiting,
resolving inflammation, and a more protracted response
leading to systemic inflammation, respectively, pMφ from
either environment displayed distinct characteristics [16].
PMφ from the protracted peritonitis had a typical Mφ1
phenotype, while those from the resolving inflammation had
characteristics of both Mφ1 and Mφ2 and were named as
resolving macrophages (rMφ). These rMφ, as compared with
Mφ1, released ex vivo fewer pro-inflammatory cytokines,
including TNFα, IL-1β, and IL-12 but more IL-10 and PGD2.
The expression of COX 2, iNOS, and intracellular cAMP
contents were also increased. Elevating cAMP levels by cAMP
analoga transformed Mφ1 to rφM, whereas cAMP inhibitors
converted rMφ to Mφ1. These findings demonstrate that
cAMP plays a central role in the regulation ofMφ phenotype.
In addition, it has been found that cyclooxygenase inhibition
improved bacterial killing and resistance to infection in
mice and humans, confirming the important role of cAMP.
Interestingly, COX 1 rather than COX 2 turned out to be
the predominant form that is active during infection [48].
Similarly, phagocytosis of apoptotic cells by Mφ proved to
inhibit the production of several mediators such as IL-1β,
TNFα, and IL-10, but it increased the production of TGF-β1,
PGE2, and PAF [49]. The latter mediators induced suppres-
sion of LPS-stimulated cytokine production by such Mφ. In
contrast, indomethacin restored the inhibition of cytokines
and inhibited TGF-β1 production by phagocytosing Mφ.
These findings show that PGE2 along with TGF-β1 and PAF
plays an actively suppressing role in the shift from a pro-
inflammatory to a more anti-inflammatory phenotype in
Mφ that have ingested apoptotic cells.
5. Conclusions and Future Perspectives
Compared with pMφ from uninfected CAPD patients, pMφ
from an infected peritoneal cavity display ex vivo an upreg-
ulation of production and secretion of pro-inflammatory
cytokines and a downregulation of anti-inflammatory medi-
ators. In terms of polarized macrophage activation, these
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findings show that during infectious peritonitis the pMφ
population is on average shifted to a Mφ1 phenotype. In
the above-mentioned studies, the cells were collected when
the first signs and symptoms of peritonitis became manifest,
that is, before antibiotic treatment was started. Following
successful treatment, signs and symptoms improve within a
few days. Ex vivo studies with eﬄuents could also provide
an unique opportunity to follow up human pMφ and other
leukocytes during the resolution phase, set in motion after
antibiotics have brought about reduction and elimination
of microbes. What changes do pMφ and other leukocytes
undergo in the recovery phase during the shift from Mφ1
to a more typical Mφ2 profile? What is the time course
and how long do Mφ1 features persist? Using current
techniques including transcriptional profiling, proteomics
and flow cytometry, a better understanding of the regulation
of infection-induced inflammatory reactions in humans
may be achieved. The findings of the comparative studies
on cytokine release from pMφ from an infection-free and
infectious environment are in line with the postulate that
in vivo Mφ1 and Mφ2 are extremes of a wide spectrum of
phenotypes. Yet, the fact that Mφ2 may increase by local
proliferation rather than by recruitment, as recently found
in experimental studies, may have important implications
for the way we look at the pathogenesis and therapy of
chronic inflammatory disorders, if this interesting discovery
also applies in humans [13, 50]. Severe fibrosis and neoan-
giogenesis of the peritoneum are the histological hallmarks
of encapsulating peritoneal sclerosis (EPS), a rare but serious
complication of long-term CAPD [51–56]. Etiology and
pathogenesis are incompletely understood, but EPS may be
conceived as an extreme example of type 2 inflammation.
Histological studies and ex vivo studies of pMφ from
peritoneal eﬄuents, assuming they are representative of peri-
toneal tissue Mφ, may help to gain a better understanding of
this complication.
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